Multiple Myeloma
Phase II
Accepting Patients
nct/study# NCT04133636 / 68284528MMY2003
A Phase 2, Multicohort Open-Label Study Of JNJ-68284528, A Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA In Subjects With Multiple Myeloma (CARTITUDE 2)
Learn More
Multiple Myeloma
Phase I/II
Accepting Patients
nct/study# NCT03288493 / P-BCMA-101-001
Open-Label, Multicenter, Phase 1 Study To Assess The Safety Of P BCMA-101 In Subjects With Relapsed / Refractory Multiple Myeloma (MM) Followed By A Phase 2 Assessment Of Response And Safety (PRIME)
Learn More
Multiple Myeloma
NA
Accepting Patients
nct/study# NCT02911571 / PROMMIS
Prospective Observational Multiple Myeloma Impact Study Prospective Multicenter Study To Measure The Impact Of Mmprofiler On Treatment Intention In Active Multiple Myeloma Patients
Learn More
Multiple Myeloma
Phase I
Accepting Patients
nct/study# NCT04436029 / DC11B
Descartes-11 Consolidation Treatment In Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Learn More
Multiple Myeloma
Phase I
Accepting Patients
nct/study# NCT04398745 / GSK-209626
A Phase I Study to Evaluate the Pharmacokinetics and Safety of
belantamab mafodotin Monotherapy in Participants with Relapsed and/or Refractory
Multiple Myeloma (RRMM) Who Have Normal and Varying Degrees of Impaired Renal
Function (DREAMM 12)
Learn More
Multiple Myeloma
Phase I
Accepting Patients
nct/study# NCT04398680 / GSK-209627
A Phase I Study to Evaluate the pharmacokinetics and safety of
Belantamab Mafodotin Monotherapy in participants with Relapsed or Refractory Multiple
Myeloma who have normal and varying degrees of impaired hepatic function
(DREAMM 13)
Learn More
